European Journal of Biomedical and Pharmaceutical Sciences

A CASE REPORT ON AMLODIPINE INDUCED PEDAL OEDEMA

Dr. C. Sugunakar Raju*, Dr. Suresh, Dr. S. Parveen, Cheepati Veera Vamsi and Danish Ahmed Khan Niyazi

ABSTRACT

Amlodipine is a 4th generation dihydropyridine calcium channel blocker which is permitted for the treatment of essential hypertension and angina pectoris. The main mechanism of calcium channel blockers are blocks the voltage sensitive L-type calcium channels by binding to alpha-1 subunit, so prevent the entry of calcium in to the cells finally no excitation-contraction coupling in the heart and vascular smooth muscles. It is absorbed slowly after oral administration. But its bioavailability is high. It has a longer duration of action than an nifedipine. It dilates both peripheral as well as coronary vessels. It is an alternative anti-hypertensive drug for patients with Nifedipine induced pedal oedema. This drug is expected to produce a more incidence of pedal oedema, as compared to Nefidipine and other calcium channel blockers, based on the limited data available from clinical trials. The common adverse effects of Amlodipine are nausea, abdominal pain, vomiting, dry mouth, constipation, gingival hypertrophy, dizziness, heartburn, photosensitivity, headache, light headedness and insomnia. We report a case of Amlodipine induced pedal oedema.

Keywords: Amlodipine, CCBs, CVA, pedal oedema, ADR analysis.